HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: A systematic review and meta-analysis

Mohamad A. Meybodi, Wenhao Cao, Leo Luznik, Asad Bashey, Xu Zhang, Rizwan Romee, Wael Saber, Mehdi Hamadani, Daniel J. Weisdorf, Haitao Chu, Armin Rashidi

Research output: Contribution to journalArticle

Abstract

HLA haploidentical hematopoietic cell transplantation (haplo-HCT) using posttransplantation cyclophosphamide (PT-Cy) is an alternative strategy when a matched sibling donor (MSD) is not available. We performed a systematic review and meta-analysis to compare the outcomes of MSD vs haplo-HCT. Eleven studies (1410 haplo-HCT and 6396 MSD recipients) were meta-analyzed. All studies were retrospective and high quality, and 9 were multicenter. Haplo-HCT was associated with ∼50% lower risk of chronic graft-versus-host disease (GVHD) (hazard ratio [HR], 0.55; 95% confidence interval [CI], 0.41-0.74), but higher risk of nonrelapse mortality (HR, 1.36; 95% CI, 1.12-1.66). Relapse, survival, acute GVHD, and GVHD-free relapse-free survival were not significantly different between the groups. Deciphering the relative contribution of PT-Cy and HLA disparity to the observed outcome differences between the groups requires further research.

Original languageEnglish (US)
Pages (from-to)2581-2585
Number of pages5
JournalBlood Advances
Volume3
Issue number17
DOIs
StatePublished - Sep 10 2019

    Fingerprint

ASJC Scopus subject areas

  • Hematology

Cite this

Meybodi, M. A., Cao, W., Luznik, L., Bashey, A., Zhang, X., Romee, R., Saber, W., Hamadani, M., Weisdorf, D. J., Chu, H., & Rashidi, A. (2019). HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: A systematic review and meta-analysis. Blood Advances, 3(17), 2581-2585. https://doi.org/10.1182/bloodadvances.2019000614